{"id":565842,"date":"2026-09-28T00:30:00","date_gmt":"2026-09-27T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=565842"},"modified":"2026-09-26T23:09:45","modified_gmt":"2026-09-26T21:09:45","slug":"o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra\/","title":{"rendered":"O inibidor da SGLT-2 dapagliflozina como tratamento complementar \u00e0 inibi\u00e7\u00e3o do SRA"},"content":{"rendered":"\n

O amplo espectro de efeitos terap\u00eauticos dos inibidores do SGLT-2 (cotransportador de s\u00f3dio-glicose 2) inclui, entre outros, a prote\u00e7\u00e3o cardiorrenal em doentes com doen\u00e7a renal cr\u00f3nica (DRC) n\u00e3o diab\u00e9tica, como comprovam de forma impressionante grandes ensaios cl\u00ednicos aleat\u00f3rios controlados (RCT) realizados em adultos (por exemplo, DAPA-CKD, EMPA-KIDNEY). Entretanto, foi lan\u00e7ado o DOUBLE PROTECT Alport, um estudo de fase III (NCT05944016), no qual se avaliam a efic\u00e1cia e a seguran\u00e7a dos inibidores da SGLT2 como tratamento complementar \u00e0 terapia padr\u00e3o em doentes com idades compreendidas entre os 10 e os 40 anos com DRC de origem gen\u00e9tica (s\u00edndrome de Alport).<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

O amplo espectro de efeitos terap\u00eauticos dos inibidores do SGLT-2 (cotransportador de s\u00f3dio-glicose 2) inclui, entre outros, a prote\u00e7\u00e3o cardiorrenal em doentes com doen\u00e7a renal cr\u00f3nica (DRC) n\u00e3o diab\u00e9tica, como……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":565844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Doen\u00e7a renal de origem gen\u00e9tica: DOUBLE PROTECT Alport","footnotes":"[{\"content\":\"taxa de filtra\\u00e7\\u00e3o glomerular estimada (eGFR) > 60 ml\\\/min\\\/1,73 m\\u00b2;<\\\/em>\",\"id\":\"de281f80-e833-44d8-8f97-4476b5bc7e6c\"},{\"content\":\"No que diz respeito \\u00e0 canagliflozina, tamb\\u00e9m um inibidor da SGLT-2, a autoriza\\u00e7\\u00e3o da Swissmedic limita-se, atualmente, \\u00e0 nefropatia diab\\u00e9tica em adultos (informa\\u00e7\\u00e3o atualizada a 3 de setembro de 2026).<\\\/em>\",\"id\":\"6d28f7e2-6362-4781-bb54-2555ce6ea639\"}]","_members_access_role":[],"_members_access_error":""},"category":[11551,11521,11524,11411,11305,11426],"tags":[23369,100924,13003,66530,23326,21481,100921,100922,24256,100925,71818,100927],"powerkit_post_featured":[],"class_list":["post-565842","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-pt","category-estudos","category-formacao-continua","category-genetica-pt-pt","category-medicina-interna-geral","category-nefrologia-pt-pt","tag-add-on-pt-pt","tag-bloqueio-do-ras","tag-ckd-pt-pt","tag-dapa-ckd-pt-pt","tag-dapagliflozin-pt-pt","tag-doenca-dos-rins","tag-double-protect-alport","tag-drc-de-origem-genetica","tag-inibidor-sglt-2","tag-nct05944016","tag-protecao-cardiorenal","tag-terapia-complementar-2","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-05 02:35:04","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":565847,"slug":"la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra","post_title":"La dapagliflozina, un inhibidor de la SGLT-2, como tratamiento complementario al bloqueo del SRA","href":"https:\/\/medizinonline.com\/es\/la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/565842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=565842"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/565842\/revisions"}],"predecessor-version":[{"id":565846,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/565842\/revisions\/565846"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/565844"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=565842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=565842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=565842"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=565842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}